- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Product Innovation & Availability
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
Status
Completed
Phase
I
Principal Investigator(s)
Christine K. Mauck
Objective
To examine the effects of two contraceptive methods and the menstrual cycle on the pharmacokinetics, pharmacodynamics of tenofovir 1% gel and the effect of the contraceptive methods on markers of mucosal safety.
Prevention Option(s)
Hormonal Contraceptives and HIV
Microbicides
Study Design
Randomized
Open label
Arms and Assigned Interventions
Description
Tenofovir 1% vaginal gel
DMPA
Mode of Delivery
Gel
Intramuscular
Products
1% tenofovir gel
DMPA
ARMs
Experimental
Description
Tenofovir 1% vaginal gel
Oral contraceptive: LNG 150 mcg and EE 30 mcg
Mode of Delivery
Gel
Tablet
Products
1% tenofovir gel
ARMs
Experimental
Official Code
Trial Sponsors
CONRAD
March 2012
March 2014
Enrollment
72
18
Years
50
Years
Population
Women
Sites
Eastern Virginia Medical School
Norfolk, Virginia
United States of America
Profamilia
Santo Domingo
Dominican Republic
University of Pittsburgh School of Medicine, Center for Family Planning Research
Pittsburgh, Pennsylvania
United States of America